首页|诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate
诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
国家科技期刊平台
NETL
NSTL
万方数据
2020-09-03,美国食品药品监督管理局(FDA)正式批准美国RadioMedix公司研发的Copper Cu 64 dotatate(商品名:Detectnet)用于成人患者生长抑素受体阳性神经内分泌肿瘤的诊断.Copper Cu 64 dotatate是一种放射性诊断试剂,与生长抑素受体结合并发射正电子(β+)的放射性核素,其发射量允许正电子发射断层扫描(PET)成像.本文现对其作用机制、药代动力学、临床研究、安全性等方面进行介绍.
Copper Cu 64 dotatate,a new diagnostic agent for somatostatin receptor-positive neuroendocrine tumors
On September 3,2020,the U.S.Food and Drug Administration(FDA)granted formal approval to Copper Cu 64 dotatate(commercially known as Detectnet),for its pivotal role in diagnosing somatostatin receptor(SSTR)positive neuroendocrine tumors(NETs)in adult patients.This innovative diagnostic agent,Copper Cu 64 dotatate,is a sophisticated radionuclide that selectively targets somatostatin receptors,facilitating the emission of positron(β+)radionuclides in a quantity conducive for high-resolution positron emission tomography(PET)imaging.This review delves into the intricate mechanisms of action,the dynamic pharmacokinetics,comprehensive clinical studies,and the safety profile of Copper Cu 64 dotatate,highlighting its significance in the realm of medical diagnostics.
Copper Cu 64 dotatateneuroendocrine tumorssomatostatin receptor
国家科技期刊平台
NSTL
万方数据
